In MesomiR-1, “TargomiRs”—EGFR-targeted, nonliving bacterial minicell nanoparticles encapsulating a miR-16 mimic—are administered intravenously in a phase I dose-escalation for recurrent malignant pleural mesothelioma and NSCLC to establish safety and the MTD via cohort-based escalation [132]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.